NILOTINIB
Generic: NILOTINIB
Cipla USA Inc.Manufacturer
ORALRoute
NILOTINIBActive Substance
2025-02-19Original Approval
NILOTINIB is FDA application NDA218922, sponsored by CIPLA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class III2026-02-18
Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, MaFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition
Class III2026-02-18
Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 IndependenceFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition
Top Reported Reactions
1
DRUG INTOLERANCE
430 reports
2
DRUG INEFFECTIVE
349 reports
3
DRUG RESISTANCE
348 reports
4
DIARRHOEA
338 reports
5
DYSPNOEA
335 reports
6
FATIGUE
325 reports
7
NAUSEA
306 reports
8
HEADACHE
302 reports
9
MYALGIA
281 reports
10
ARTHRALGIA
272 reports